GRAPHJET TECHNOLOGY (GTIJF): Nasdaq/NYSE listing notice — Energem Corp. receives Nasdaq delisting notice for failure to maintain 400 shareholders

GRAPHJET TECHNOLOGY

Received Nasdaq notice on Dec 4, 2023 for failing to maintain minimum 400 shareholders for continued listing.
Company requested hearing before Nasdaq Panel; hearing scheduled for March 21, 2024.
Hearing request stays suspension of trading; securities continue trading on Nasdaq Capital Market pending panel decision.
No assurance that panel will grant continued listing or delisting suspension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding shareholders.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders

Exact text from the filing

received a notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) t hat the Company no longer has the minimum required 400 shareholders for continued listing on Nasdaq. Accordingly, the Company’s securities will be delisted unless the Company requests an appeal of this determination as described below . The Company has requested a hearing before the Panel to appeal this Notice as well as the notice received on November 22, 2023, which was previously disclosed on Form 8-K filed on November 28, 2023. Nasdaq has granted the Company’s hearing request, which is

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GRAPHJET TECHNOLOGY filing history →

Source: SEC EDGAR

accession 0001493152-23-044110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.